Will there be an H5N1 avian flu outbreak in the U.S. requiring federal emergency response by the end of 2025?
Yes • 50%
No • 50%
U.S. government or CDC announcements regarding emergency response to H5N1
U.S. Awards Moderna $590 Million for H5N1 Bird Flu Vaccine mRNA-1018 Development
Jan 17, 2025, 10:07 PM
The U.S. Department of Health and Human Services (HHS) has awarded Moderna Inc. $590 million to advance the development of a vaccine against bird flu, specifically targeting the H5N1 strain. This funding is in addition to the $176 million HHS provided last year for the late-stage development and testing of a pre-pandemic mRNA-based vaccine against H5N1 avian influenza. The investment aims to accelerate the development of Moderna's mRNA-1018 vaccine, which is currently in a Phase 1/2 study to assess its safety and immunogenicity in healthy adults and is planned for Phase 3 trials in 2025. The Biden-Harris Administration has emphasized the importance of this initiative, citing the unpredictability and danger of avian flu variants, including H5 and H7, to humans. This move is part of a broader effort by the administration, which also includes a $306 million investment to enhance disease surveillance, laboratory testing, and monitoring of the H5N1 avian flu's impact.
View original story
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Negative immunogenicity results • 25%
Study inconclusive • 25%
Positive safety and immunogenicity results • 25%
Negative safety results • 25%
U.S. Government • 25%
Other • 25%
International Organizations • 25%
Private Investors • 25%